Saturday, October 31, 2026

GBP/EUR Over 1% Up In The Last 10 Sessions

ViaNews Editorial Team

December 1, 2023

GBP/EUR Over 1% Up In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.36% for the last 10 sessions. At 07:10 EST on Friday, 1 December, GBP/EUR (GBPEUR) is $1.16.

GBP/EUR's yearly highs and lows, it's 4.104% up from its 52-week low and 1.512% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was 0.16%, 0.03%, and 0.19%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.16% (last week), 0.20% (last month), and 0.19% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd price analysis: the key contention level is seen at 1.0930. According to FXStreet on Thursday, 30 November, "The EUR/USD pair trades with modest intraday losses during the early European session on Thursday. ", " From the technical perspective, EUR/USD maintains a positive vibe as the major holds above the 50- and 100-hour Exponential Moving Averages (EMA) on the four-hour chart. "
  • Eur/usd slipping back as the 1.1000 handle begins to look more like a ceiling that a goal. According to FXStreet on Wednesday, 29 November, "The Euro has climbed over 5% against the US Dollar since October's swing low into 1.0450, and the EUR/USD is holding in the green for the year, but 2023's mid-year peak at 1.1275 is weighing on the long-term trend as the pair gets weighed down near 1.1000 with technical indicators leaning into overbought territory.", "The EUR/USD has been on a steady climb ever since the Euro crashed through the 200-day Simple Moving Average (SMA) near 1.0800, and the pair is running into technical resistance from the 1.1000 handle."
  • Eur/usd maintains its position above 1.1000 ahead of Spain, Germany CPI data. According to FXStreet on Wednesday, 29 November, "The EUR/USD pair is benefiting from the softer US Dollar (USD), which is influenced by a less hawkish stance from the US Federal Reserve (Fed)."
  • Eur/usd forex signal: head and shoulders pattern forms - 29 November 2023. According to DailyForex on Wednesday, 29 November, "The EUR/USD will be in the spotlight on Wednesday as the US publishes the second estimate of Q3 GDP data. ", "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bearish viewSell the EUR/USD pair and set a take-profit at 1.0900."
  • According to FXStreet on Thursday, 30 November, "At the time of writing, the EUR/USD is dropping 0.05% on the day to trade at 1.0971."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com